Amna Nabeel Khan, MD, FACE, CCD
Endocrinology
Headshot of Amna Nabeel Khan, MD, FACE, CCD

Amna Nabeel Khan, MD, FACE, CCD

Endocrinology
Accepting new patients
Sees patients age 18 and up
Penn Endocrinology Perelman
Headshot of Amna Nabeel Khan, MD, FACE, CCD
Penn Medicine Provider

About me

  • Co-Director, Penn Bone Center
  • Professor of Clinical Medicine (Endocrinology, Diabetes and Metabolism)

My education and training

  • King Edward Medical CollegeMedical School
  • University of Tennessee Health Science CenterResidency
  • Long Island College HospitalResidency
  • University of Tennessee Health Science CenterFellowship

Spoken languages

English
English

Reviews

Average Rating

392 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

Anonymous
October 2026
Dr Khan is a rare expert in bone health and cares for her patients so compassionately and completely.
Anonymous
October 2026
Dr Khan is very thorough and focuses on my individual health needs
Anonymous
October 2026
Professional and knowledgeable
Anonymous
October 2026
I feel Dr Amna Khan is very thorough , answers questions, listens to my concerns and addresses them. Works with me to develop a plan to manage my condition for the best possible outcome.. always returns texts via portal or phone. I highly recommend her expertise

Insurance accepted

Please contact the practice and/or the member services department of your insurance company for specific details before receiving services. Providers may participate in some, but not all, products offered by a health plan; providers may also accept plans at some practice locations but not others.

Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
Dr. Khan is a Penn Medicine provider.

Qualifications and experience

All conditions and treatments

Research

Publications

Anna Zuschnitt, Erin Lightheart, Jennifer Myers, Amna N Khan Impact of Clinical Pharmacist-Led Interventions on Denosumab Adherence. , Archives of Osteoporosis: 2026


Dania Salih-Bacha, Anna Zuscnitt, Julia Cabral, Amna N. Khan Romosozumab After Long Term Denosumab: Real-World Outcomes Diverge From Clinical Trial Expectations. , Annual meeting of American Society of Bone and Mineral Research Oct: 2026


Alexander A. Boyko, Amna N. Khan, Kate E. Temme Sequential Osteoanabolic and Anti resorptive Therapy in a Young Female Athlete with RED-S, Low Bone Density and Recurrent Bone Stress Injuries , Annual meeting of American Society of Bone and Mineral Research October: 2026


Riddhi Amin, Riya Madan, Joshua F. Baker, Brian S. Englander, Amna N. Khan, Anupama Shahane. Technologist vs Physician FRAX: Systematic Underestimation of Fracture Risk at Higher Thresholds , Presented -Philadelphia Endocrine Society Meeting May -Perelman School of Medicine Annual Research Day, June -Annual meeting of American Society of Bone and Mineral Research, Oct: 2026


Rashad Madi, David R. Weber, Michael A. Levine, Babette S. Zemel, Joshua F. Baker, Amna N. Khan Height Related Bias in DXA Derived Areal Bone Mineral Density among US Adults , Presented at the Annual meeting of American Society of Bone and Mineral Research Oct: 2026


Marianne Riordan and Amna N. Khan Efficacy of Romosozumab After Long-Term Denosumab Therapy-A Case Report , Annual Meeting of Endocrine Society: 2025


Amna N. Khan, Robert B. Jones Jr, Nabeel Khan, Yu‑Xiao Yang,Robert A. Adler Trends in hip fracture rates in US male veterans , Osteoporosis International: 2024


Rashad Madi, Sarem Khan, Chamith S. Rajapakse, Amna N. Khan and Kate Temme Can Trabecular Bone score Enhance Fracture Risk Assessment in Long Distance Runners with bone Stress Injuries? , Clinical Journal of Sports Medicine: 2024


Lin JK, Hearn CM, Getzen E, Long Q, Lee DC, Keaveny TM, Jayadevappa R, Robinson KW, Wong YN, Maxwell KN, Narayan V, Haas NB, Takvorian SU, Bikle DD, Chiang JM, Khan AN, Rajapakse CS, Morgans AK, Parikh RB. Validation of Biomechanical Computed Tomography for Fracture Risk Classification in Metastatic Hormone-sensitive Prostate Cancer. , Eur Urol Oncol. 2023 Nov 3:S2588-9311(23)00230-4. doi: 10.1016/j.euo.2023.10.016: 2023


Amna N. Khan, MD, Jaliyah Johnson, BSN, Alexia Tsikouras, PharmD, Anna Zuschnitt, PharmD Reduction in the Non-adherence Rate to Denosumab Therapy with Clinical Pharmacy Collaboration: A Quality Improvement Project in an Osteoporosis Clinic , PRESENTED AT THE ANNUAL MEETING OF ASBMR IN VANCOUVER. OCTOBER: 2023